Evosep Biosystems’ Post

It was insightful to listen to what investors are after in regard to biopharmacology. As Advalyst, continues to boost its idea-stage biopharma start-up (advanced cancer inhibitors) founding team, scanning the worldwide VC investment landscape, is educating. #bioengineering #computationalpharmacology #ai #clinicaltrialsimulators #opensourceAI

I am glad to share the news that my research paper "Development and Bioactivity Assessment of a Recombinant Pseudomonas aeruginosa Azurin-BR2 Peptide Fusion Protein: A Novel Approach to Cancer Immunotherapy" has been published in the "Journal of Biological Regulators and Homeostatic Agents". #JournalofBiologicalRegulatorsandHomeostaticAgents #Researchpaper #Molecularbiology #Recombinantdnatechnology

Glad to see our latest review paper "Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions" accepted for publication in Biomolecules MDPI journal. https://lnkd.in/d8SYyRv6 In this work, together with Denys Bondar , who spent year(s) of his PhD journey on this topic☝️, we reviewed the properties, characteristics, and challenges of PARP inhibitors, discussing their development from first-generation to third-generation compounds, more #green and #sustainable routes for synthesis of new anti-cancer agents, their mechanisms of therapeutic action, and potential for targeting additional biological targets beyond the catalytic active site of PARP proteins.

🔬 Recent studies demonstrate the use of microcarriers for large-scale production of HEK293T cells—a challenging task when working with adherent cells. The research focuses on screening active compounds from Fructus evodiae targeting the FGFR4 receptor, which plays a key role in cancer therapy. By utilizing microcarrier technology, the study shows how drug screening can be more efficient and biomimetic, mimicking in vivo conditions for better results. Learn more about this innovative method and its applications on our website 👉: https://lnkd.in/gu6nj7zk Do you need help with large-scale expansion of HEK293T cells? Reach out to our panel of experts to help you adapt to microcarrier culture: info@smartmcs.com.au #HEK293T #CellCulture #Microcarriers #DrugDiscovery #CancerResearch #Biotech #ScalingScience

Single Cell Proteomics at Scale Getting really clear on the proteins you are interested in allows you to crank up the throughput to analyze more cells than previously thought to be feasible. Benjamin Orsburn used the Evosep One to show this with cancer cells, analyzing up to 3,500 cells per day! When it comes to Single Cell Proteomics, biological insight is about more than just maximizing protein IDs. https://lnkd.in/edJ8qbbu #lcms #singlecell #proteomics

Exciting news from Calculus portfolio company Oxford BioTherapeutics (OBT) - the first patient has been dosed with its lead candidate, OBT076, in a Phase 1b trial in adenoid cystic carcinomas (ACC) of the head and neck. OBT076 was discovered using OBT’s proprietary OGAP® platform, which is the world’s largest cancer specific, membrane protein library used to identify novel, high specific antigens for cancer targets. Click here to read more: https://lnkd.in/eNqHDa7W #immunotherapy #oncology #cancerresearch #biotech #eis #vct Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong.

Roth Capital's latest Equity Research on Imugene Limited (ASX:IMU) highlights their continued positive outlook, maintaining a "Buy" rating with a 12-month price target of AUD $0.42. This valuation is based on robust clinical developments and strong financial health, notably their MAST trial for solid tumours. Key data from this trial support the potential of Imugene's innovative cancer treatments, positioning the company well for future growth. #Imugene #BiotechInvesting #CancerResearch #IMU #EquityResearch #smallcaps #smallcapstocks #cancer #biotech

Pioneering Medical Research with Terbium-161 🔬 Terbium-161 exhibits exciting potential as a radiopharmaceutical element. With its ability to emit beta radiation, it can precisely target cancer cells, providing prospects for more effective therapeutic solutions. Bellow is a scan we acquired using our benchtop modality, the γ-eye, on a healthy subject. We are excited to provide scientists with the tools they need. Embracing them translate ideas, into outcomes. #molecularimaging #research #terbium161 #theranostics

New hope in #Cancer treatment! Scripps Research team identifies potential targets for future cancer drugs using an innovative protein-mapping approach. Findings may enable researchers to create more precise therapies to stop cell multiplication. Quick Read: https://lnkd.in/gA_kxkdQ #Bioinformatics #CancerResearch #DrugDiscovery #ScienceNews #biotechnology

Metagenomics provide unique interdisciplinary opportunity for researchers to be at the forefront of drug discovery Most antibiotics and many common cancer, chemotherapy, and cholesterol-lowering drugs originate from microbes. Although researchers have identified many microbial-derived bioactive molecules by culturing microbes, as many as two to three orders of magnitude more microorganisms may be resistant to laboratory culture. Metagenomics offers a culture-independent approach to tap into the unexplored microbial world